Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.

ABSTRACT: The introduction of molecularly targeted therapies (TTs) has transformed the management of metastatic renal cell carcinoma (mRCC). Within a relatively short period of time, systemic treatment of mRCC has evolved from a disease treated only by cytokines to a disease where TT is the cornerstone of patient management. Since the approval of sorafenib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), in December 2005, 7 drugs have been introduced that have provided a high level of clinical efficacy in patients with mRCC, with a median survival of ~30 months in an unselected patient population that generally fits trials eligibility. Despite such success, advancements in therapies have reached a plateau: different combinations of targeted agents have not demonstrated additiona

SUBMITTER: de Velasco G 

PROVIDER: S-EPMC4654640 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature